BIOMAT Database Logo BIOMAT Database Logo

[Mutation-specific antibodies for detection of epidermal growth factor receptor mutations in patients with lung adenocarcinoma]. 2013

Qing Zhang, and Jie Zhang
Department of Pathology, Shanghai Jiaotong University, Shanghai, China.

OBJECTIVE To examine the sensitivity and specificity of the two epidermal growth factor receptor hotspot mutation antibodies-delE746-A750 and L858R in lung adenocarcinoma, and to discuss the value of the two antibodies for detecting these two "classic mutations" by immunohistochemistry. METHODS With Q-scoring assessment and ROC curve analysis,immunohistochemistry was used to screen a panel of 309 paraffin-embedded non-small cell lung cancer(NSCLC) tumor samples, of which EGFR gene mutational status was previously documented by PCR-DNA sequencing. RESULTS Three hundred and nine NSCLC tumor samples conclude 92 NSCLC cases with 19delE746-A750 and 110 with 21L858R. Using DelEGFR antibody to detect 19delE746-A750 demonstrated sensitivity and specificity of 84.8% (78/92) and 77.6% (83/107), respectively. Choosing the best cut-off value of 85.00, it achieved the maximum area under the curve (AUC:0.885). L858R antibody to detect 21L858R showed sensitivity and specificity of 94.5% (104/110) and 62.5% (55/88), respectively. Choosing the best cut-off value of 97.50, it achieved the maximum area under the curve (AUC:0.924). CONCLUSIONS By using Q-scoring assessment and ROC curve analysis, the two antibodies (delEGFR and L858R) can been used to identify EGFR gene mutations present in lung adenocarcinomas.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

Qing Zhang, and Jie Zhang
Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
May 2014, Histopathology,
Qing Zhang, and Jie Zhang
Epidermal growth factor receptor mutations in adenocarcinoma lung: Comparison of techniques for mutation detection.
January 2022, Indian journal of pathology & microbiology,
Qing Zhang, and Jie Zhang
Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
February 2013, Diagnostic pathology,
Qing Zhang, and Jie Zhang
Epidermal growth factor receptor mutations in lung adenocarcinoma.
February 2014, Laboratory investigation; a journal of technical methods and pathology,
Qing Zhang, and Jie Zhang
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies.
September 2016, Lung cancer (Amsterdam, Netherlands),
Qing Zhang, and Jie Zhang
Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients.
June 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Qing Zhang, and Jie Zhang
Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
March 2019, Cancer biotherapy & radiopharmaceuticals,
Qing Zhang, and Jie Zhang
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
October 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Qing Zhang, and Jie Zhang
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
January 2021, BMC cancer,
Qing Zhang, and Jie Zhang
Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry.
December 2017, Molecular and clinical oncology,
Copied contents to your clipboard!